呼吸器合胞体ウイルス(RSV)感染症:治療薬開発パイプライン動向(2016年下半期版)

◆英語タイトル:Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2016
◆商品コード:DATA70209242
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2016年11月9日
◆ページ数:267
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Site LicenseUSD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD6,000 ⇒換算¥660,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における呼吸器合胞体ウイルス(RSV)感染症の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・呼吸器合胞体ウイルス(RSV)感染症の概要
・呼吸器合胞体ウイルス(RSV)感染症治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・呼吸器合胞体ウイルス(RSV)感染症パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・呼吸器合胞体ウイルス(RSV)感染症治療薬開発に取り組んでいる企業:企業別製品パイプライン
・呼吸器合胞体ウイルス(RSV)感染症治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Respiratory Syncytial Virus (RSV) Infections – Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Respiratory Syncytial Virus (RSV) Infections – Pipeline Review, H2 2016, provides an overview of the Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline landscape.

Respiratory syncytial virus (RSV) infection is a respiratory disease. It infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache and fever. Treatment includes proper medication and hygiene practice.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Respiratory Syncytial Virus (RSV) Infections – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 12, 11, 50 and 14 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 4, 13 and 4 molecules, respectively.Respiratory Syncytial Virus (RSV) Infections.

Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
Introduction 6
Respiratory Syncytial Virus (RSV) Infections Overview 7
Therapeutics Development 8
Respiratory Syncytial Virus (RSV) Infections – Therapeutics under Development by Companies 10
Respiratory Syncytial Virus (RSV) Infections – Therapeutics under Investigation by Universities/Institutes 14
Respiratory Syncytial Virus (RSV) Infections – Pipeline Products Glance 15
Respiratory Syncytial Virus (RSV) Infections – Products under Development by Companies 18
Respiratory Syncytial Virus (RSV) Infections – Products under Investigation by Universities/Institutes 23
Respiratory Syncytial Virus (RSV) Infections – Companies Involved in Therapeutics Development 25
Respiratory Syncytial Virus (RSV) Infections – Therapeutics Assessment 85
Drug Profiles 95
Respiratory Syncytial Virus (RSV) Infections – Dormant Projects 237
Respiratory Syncytial Virus (RSV) Infections – Discontinued Products 242
Respiratory Syncytial Virus (RSV) Infections – Product Development Milestones 243
Appendix 254

List of Tables
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H2 2016 20
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis, H2 2016 21
Number of Products under Development by Companies, H2 2016 22
Number of Products under Development by Companies, H2 2016 (Contd..1) 23
Number of Products under Development by Companies, H2 2016 (Contd..2) 24
Number of Products under Development by Companies, H2 2016 (Contd..3) 25
Number of Products under Investigation by Universities/Institutes, H2 2016 26
Comparative Analysis by Late Stage Development, H2 2016 27
Comparative Analysis by Clinical Stage Development, H2 2016 28
Comparative Analysis by Early Stage Development, H2 2016 29
Products under Development by Companies, H2 2016 30
Products under Development by Companies, H2 2016 (Contd..1) 31
Products under Development by Companies, H2 2016 (Contd..2) 32
Products under Development by Companies, H2 2016 (Contd..3) 33
Products under Development by Companies, H2 2016 (Contd..4) 34
Products under Investigation by Universities/Institutes, H2 2016 35
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 36
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Abivax SA, H2 2016 37
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Ablynx NV, H2 2016 38
Respiratory Syncytial Virus (RSV) Infections - Pipeline by ADMA Biologics, Inc., H2 2016 39
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Agilvax, Inc., H2 2016 40
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2016 41
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Artificial Cell Technologies, Inc., H2 2016 42
Respiratory Syncytial Virus (RSV) Infections - Pipeline by AstraZeneca Plc, H2 2016 43
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aviragen Therapeutics, Inc., H2 2016 44
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Bavarian Nordic A/S, H2 2016 45
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Celltrion, Inc., H2 2016 46
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Codagenix, Inc., H2 2016 47
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Curevac AG, H2 2016 48
Respiratory Syncytial Virus (RSV) Infections - Pipeline by DBV Technologies S.A., H2 2016 49
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Emergent BioSolutions Inc., H2 2016 50
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Enanta Pharmaceuticals, Inc., H2 2016 51
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Evec, Inc., H2 2016 52
Respiratory Syncytial Virus (RSV) Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 53
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Gene Techno Science Co., Ltd., H2 2016 54
Respiratory Syncytial Virus (RSV) Infections - Pipeline by GenVec, Inc., H2 2016 55
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Gilead Sciences, Inc., H2 2016 56
Respiratory Syncytial Virus (RSV) Infections - Pipeline by GlaxoSmithKline Plc, H2 2016 57
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Globavir Biosciences, Inc., H2 2016 58
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Humabs BioMed SA, H2 2016 59
Respiratory Syncytial Virus (RSV) Infections - Pipeline by iBio, Inc., H2 2016 60
Respiratory Syncytial Virus (RSV) Infections - Pipeline by ILiAD Biotechnologies, LLC, H2 2016 61
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Ilyang Pharmaceutical Co., Ltd, H2 2016 62
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Immunovaccine Inc, H2 2016 63
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 64
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Johnson & Johnson, H2 2016 65
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 66
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Kineta, Inc., H2 2016 67
Respiratory Syncytial Virus (RSV) Infections - Pipeline by mAbxience S.A., H2 2016 68
Respiratory Syncytial Virus (RSV) Infections - Pipeline by MedImmune LLC, H2 2016 69
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Medivir AB, H2 2016 70
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Merck & Co., Inc., H2 2016 71
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Mucosis B.V., H2 2016 72
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Mymetics Corporation, H2 2016 73
Respiratory Syncytial Virus (RSV) Infections - Pipeline by NanoBio Corporation, H2 2016 74
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Navigen Pharmaceuticals, Inc., H2 2016 75
Respiratory Syncytial Virus (RSV) Infections - Pipeline by NeuClone Pty Ltd, H2 2016 76
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Novavax, Inc., H2 2016 77
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Panacea Biotec Limited, H2 2016 78
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Profectus BioSciences, Inc., H2 2016 79
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Pulmocide Ltd, H2 2016 80
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 81
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Romark Laboratories, L.C., H2 2016 82
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spider Biotech, H2 2016 83
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2016 84
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 85
Respiratory Syncytial Virus (RSV) Infections - Pipeline by TechnoVax, Inc., H2 2016 86
Respiratory Syncytial Virus (RSV) Infections - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016 87
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Themis Bioscience GmbH, H2 2016 88
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Trellis Bioscience, Inc., H2 2016 89
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Vault Pharma Inc., H2 2016 90
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Vaxart Inc, H2 2016 91
Respiratory Syncytial Virus (RSV) Infections - Pipeline by VaxInnate Corporation, H2 2016 92
Respiratory Syncytial Virus (RSV) Infections - Pipeline by VBI Vaccines Inc, H2 2016 93
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Virometix AG, H2 2016 94
Respiratory Syncytial Virus (RSV) Infections - Pipeline by Visterra, Inc., H2 2016 95
Respiratory Syncytial Virus (RSV) Infections - Pipeline by VLP Biotech, Inc., H2 2016 96
Assessment by Monotherapy Products, H2 2016 97
Assessment by Combination Products, H2 2016 98
Number of Products by Stage and Target, H2 2016 100
Number of Products by Stage and Mechanism of Action, H2 2016 102
Number of Products by Stage and Route of Administration, H2 2016 104
Number of Products by Stage and Molecule Type, H2 2016 106
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H2 2016 249
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..1), H2 2016 250
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..2), H2 2016 251
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..3), H2 2016 252
Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..4), H2 2016 253
Respiratory Syncytial Virus (RSV) Infections - Discontinued Products, H2 2016 254

List of Figures
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H2 2016 20
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis, H2 2016 21
Number of Products under Development by Companies, H2 2016 22
Number of Products under Investigation by Universities/Institutes, H2 2016 26
Comparative Analysis by Clinical Stage Development, H2 2016 28
Comparative Analysis by Early Stage Products, H2 2016 29
Assessment by Monotherapy Products, H2 2016 97
Number of Products by Top 10 Targets, H2 2016 99
Number of Products by Stage and Top 10 Targets, H2 2016 99
Number of Products by Mechanism of Actions, H2 2016 101
Number of Products by Stage and Mechanism of Actions, H2 2016 101
Number of Products by Routes of Administration, H2 2016 103
Number of Products by Stage and Routes of Administration, H2 2016 103
Number of Products by Top 10 Molecule Types, H2 2016 105
Number of Products by Stage and Top 10 Molecule Types, H2 2016 105

【レポートのキーワード】

呼吸器合胞体ウイルス(RSV)感染症

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 呼吸器合胞体ウイルス(RSV)感染症:治療薬開発パイプライン動向(2016年下半期版)(Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2016)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆